Retrovirus Epidemiology Donor Study (REDS) General Leukocyte/Plasma Repository (GLPR) - Catalog

Name

Retrovirus Epidemiology Donor Study (REDS) General Leukocyte/Plasma Repository (GLPR)

Accession Number

HLB01890909a

Acronym

REDS-GLPR

Related studies

BSI Study IDs

RD2

Is public use dataset

False

Keywords

Has Study Datasets

False

Has Specimens

True

Specimen ID Type

Coded

Study Website

The Framingham Heart Study Group requires that the requestor must obtain full or expedited IRB/Ethics Committee review and approval to obtain these data. Waivers or a determination that the research is exempt from ethical regulations do not suffice.

False

Clinical Trial URLs
https://clinicaltrials.gov/ct2/show/NCT00005278
Study type

Epidemiology Study

Collection Type

Open BioLINCC Study

Cohort type

Adult

Interventions

Study Open Date (Data)

None

Study Open Date (Specimens)

2009-10-01

Date materials available

2009-09-02

Last updated

2021-11-04

Study period

1994-1995

Study Contacts
NHLBI Division

DBDR

Classification

Transfusion Medicine

HIV study classification

HIV-Related

COVID study classification

non-COVID

Pre-Website # of Specimens Shipped

60779

# of Returned Specimens

62310

Primary Publication URLs
N/A
Conditions

Acquired Immunodeficiency Syndrome
Blood Donors
Blood Transfusion
HIV Infections
HIV-1
HIV-2
HTLV-I
HTLV-II
Retroviridae Infections

Objectives

To provide researchers with an opportunity to conduct studies on a large representative sample of blood donors with linked demographic data and donation test results. Targeted investigations on particular subsets of the donor population are also feasible due to the availability of this linked data.

Background

The Retrovirus Epidemiology Donor Study (REDS) has been conducted since 1989. One of the aims of this study is to establish blood specimen repositories for future testing. The General Leukocyte and Plasma Repository (GLPR) was established under this study.


The GLPR repository has already been used to investigate HHV-8 antibody prevalence in the US blood supply (1) and polymorphisms in chemokine receptor genes (2).

Participants

The GLPR was collected in 1994 and 1995 and consists of aliquots of plasma, and whole blood frozen, with or without DMSO, obtained from 147,915 blood donations.

Design

Specimens for the GLPR repository were collected according to a statistical sampling plan, designed to obtain donations that are representative of all donor racial/ethnic groups. REDS blood centers that have contributed to the GLPR repository include: the American Red Cross (ARC) Greater Chesapeake and Potomac (Baltimore, MD; and Washington, DC), Southeastern Michigan (Detroit, MI), and Southern California (Los Angeles, CA) regions; the Blood Centers of the Pacific (BCP; San Francisco, CA); and the Oklahoma Blood Institute (Oklahoma City, OK).


Donor screening and testing was performed according to standard operating procedures and included tests for anti-HIV (types 1 and 2), anti-HCV, anti-HTLV, HBsAg and anti-HBc; serologic testing for syphilis and testing for ALT levels (3).

Conclusions

Disease classification

Publications



  1. Pellett PE, et al. (2003) Multicenter comparison of serologic assays and estimation of human herpesvirus 8 seroprevalence among US blood donors. Transfusion 43(9):1260-1268. DOI: 10.1046/j.1537-2995.2003.00490.x




  2. Mariani R, et al. (1999) CCR2-64I polymorphism is not associated with altered CCR5 expression or coreceptor function. (Translated from eng) J Virol 73(3):2450-2459. DOI: 10.1128/JVI.73.3.2450-2459.1999




  3. Zuck TF, et al. (1995) The Retrovirus Epidemiology Donor Study (REDS): rationale and methods. (Translated from eng) Transfusion 35(11):944-951. DOI: 10.1046/j.1537-2995.1995.351196110900.x



Mat types

Plasma
Whole Blood

Network

Retrovirus Epidemiology Donor Study I (REDS I)

Please note that biospecimen availability is subject to review by the NHLBI, BioLINCC, and the NHLBI Biorepository. Certain biospecimens may not be made available for your request. PDF Section 3.0 of the BioLINCC Handbook describes the components of the review process.

  • Material Types
  • General Freeze/Thaw Status
  • Visits (Vials)

    24 July 2023
     

    Plasma Whole Blood Total
    Subjects with 1 Draw 121,623 245,985 367,608
    Subjects with 2 Draws 13,412 26,624 40,036
    Subjects with 3 Draws 2,073 4,222 6,295
    Subjects with 4-10 Draws 764 1,558 2,322

    Last Modified: July 24, 2023, 9:35 a.m.
  • Visits (Subjects)

    24 July 2023

    Plasma
    Total number of subjects Average volume (ml) per subject
    Subjects with 1 Draw 120,436 1.51
    Subjects with 2 Draws 13,370 1.50
    Subjects with 3 Draws 2,071 1.50
    Subjects with 4-10 Draws 504 2.26
     
      Whole Blood
    Total number of subjects Average volume (ml) per subject
    Subjects with 1 Draw 126,993 0.99
    Subjects with 2 Draws 13,532 1.01
    Subjects with 3 Draws 2,104 1.05
    Subjects with 4-10 Draws 509 1.60

    Last Modified: July 24, 2023, 9:35 a.m.